Similar articles

• Changes in inflammatory biomarkers in SWORD-1 and SWORD-2 studies.

  Serrano-Villar S, Moreno S. Serrano-Villar S, et al. Lancet HIV. 2020 Mar;7(3):e158. doi: 10.1016/S2352-3018(20)30028-X. Lancet HIV. 2020. PMID: 32142710 No abstract available.
• Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

  Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA, Adkison K, Underwood M, Matthews JE, Wynne B, Vandermeulen K, Gartland M, Smith K. Aboud M, et al. Lancet HIV. 2019 Sep;6(9):e576-e587. doi: 10.1016/S2352-3018(19)30149-3. Epub 2019 Jul 12. Lancet HIV. 2019. PMID: 31307948 Clinical Trial.
• Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

  Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M. Llibre JM, et al. Lancet. 2018 Mar 3;391(10123):839-849. doi: 10.1016/S0140-6736(17)33095-7. Epub 2018 Jan 6. Lancet. 2018. PMID: 29310899 Clinical Trial.
• Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults.

  Properzi M, Magro P, Castelli F, Quiros-Roldan E. Properzi M, et al. Expert Rev Anti Infect Ther. 2018 Dec;16(12):877-887. doi: 10.1080/14787210.2018.1544491. Epub 2018 Nov 14. Expert Rev Anti Infect Ther. 2018. PMID: 30392419 Review.
• New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.

  Ribera E. Ribera E. AIDS Rev. 2018;20(4):179-186. doi: 10.24875/AIDSRev.M18000026. AIDS Rev. 2018. PMID: 30548024 Review.